Prosecution Insights
Last updated: May 29, 2026
Application No. 17/257,968

Methods for Multicolor Multiplex Imaging

Non-Final OA §112
Filed
Jan 05, 2021
Priority
Jul 09, 2018 — provisional 62/695,381 +2 more
Examiner
EMCH, GREGORY S
Art Unit
1678
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ultivue, Inc.
OA Round
3 (Non-Final)
49%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
305 granted / 623 resolved
-11.0% vs TC avg
Strong +44% interview lift
Without
With
+44.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
32 currently pending
Career history
662
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
47.4%
+7.4% vs TC avg
§102
15.3%
-24.7% vs TC avg
§112
11.6%
-28.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 623 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s response on 1/22/2026 has been received and entered. Claims 11, 16-20 have been canceled. Claims 1-10 and 12-15 are pending and under examination. Obvious type double patenting over 18435336 (now US12417538) is withdrawn because 538’ patent does not recite the one imager strand comprises at least two different types of labels. Moreover, 538’ patent does not recite that the total labels Nch is smaller than total targets Nm (where m is at least 3, and Nch is at least 2). The rejection on claims 1-10, 12-15 under 35 USC 112(b) is withdrawn because of amendment. However a new ground of rejection is set forth below. Note, telephonic call was made to Dr. Anderson but no response has been received since. Examiner suggests applicants provide more information in the future for expediting prosecution, e.g. name of the law firm, fax number or email. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 15 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. As to claim 15, step 4, the "e.g." renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Conclusion Claims 1-10 and 12-14 are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHANGHWA J CHEU whose telephone number is (571)272-0814. The examiner can normally be reached 8 am to 8 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gregory Emch can be reached at 5712728149. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CHANGHWA J. CHEU Primary Examiner Art Unit 1678 /CHANGHWA J CHEU/Primary Examiner, Art Unit 1678
Read full office action

Prosecution Timeline

Jan 05, 2021
Application Filed
Jan 03, 2025
Non-Final Rejection mailed — §112
Jul 02, 2025
Response Filed
Aug 21, 2025
Examiner Interview (Telephonic)
Sep 22, 2025
Final Rejection mailed — §112
Jan 22, 2026
Response after Non-Final Action
Feb 04, 2026
Examiner Interview (Telephonic)
Feb 09, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12624117
ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES
5y 2m to grant Granted May 12, 2026
Patent 12600799
ANTI-IgG NANOBODIES
6y 0m to grant Granted Apr 14, 2026
Patent 12570710
TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN THE TREATMENT OF CANCER
5y 10m to grant Granted Mar 10, 2026
Patent 12332252
GFAP ACCUMULATING IN STROKE
6y 1m to grant Granted Jun 17, 2025
Patent 12138261
INHIBITORS OF BCL-2
2y 9m to grant Granted Nov 12, 2024
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
49%
Grant Probability
93%
With Interview (+44.3%)
3y 7m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 623 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month